Advanced Search
CHEN Yi-feng, ZHANG Bai-ling, HUANG Yun-peng, LIAN Yun-zong. Relationship between Expression of hPF4mRNA, Concentration of Plasma PF4 and Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 162-162. DOI: 10.3971/j.issn.1000-8578.2010.02.010
Citation: CHEN Yi-feng, ZHANG Bai-ling, HUANG Yun-peng, LIAN Yun-zong. Relationship between Expression of hPF4mRNA, Concentration of Plasma PF4 and Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 162-162. DOI: 10.3971/j.issn.1000-8578.2010.02.010

Relationship between Expression of hPF4mRNA, Concentration of Plasma PF4 and Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma

More Information
  • Received Date: November 28, 2008
  • Revised Date: January 15, 2009
  • Objective To explore the relationship between expression of human platelet factor 4(hPF4)mRNA, concentration of Plasma PF4 and cervical lymph node metastasis in papillary thyroid carcinoma(PTC). Methods RT-PCR technique was utilized to detect the expression of hPF4 mRNA in 40 cases of PTC and 10 cases of normal tissue surrounding carcinoma. Meanwhile enzyme-linked immunosorbant assay(ELISA) technique was used to measure the concentration of PF4 in plasma of all 40 patients with PTC and 20 healthy persons as control. Results (1)The positive expression rate of hPF4 mRNA of PTC and normal tissues was 47.5% and 80%,respectively. The positive expression rate of hPF4 mRNA of PTC tissue was significantly lower than that of normal tissues(P<0.01). Furthermore the metastatic rate of cervical lymph node of PTC with hPF4 mRNA positive expression was significantly lower than that of PTC with hPF4 mRNA negative expression (36.84% vs. 90.48%)(P<0.01). (2) The concentration of PF4 in plasma of normal healthy person, PTC with cervical lymph node metastasis and PTC without cervical lymph node metastasis was in linear progressive decreasing tendency. The plasma concentration of PF4 in PTC without cervical lymph node metastasis[(2.96±0.21)ng/ml] was higher than that in PTC with cervical lymph node metastasis[(0.98±0.17)ng/ml](P<0.05). (3) The plasma concentration of PF4 in PTC with hPF4 mRNA positive expression was higher than that in PTC with hPF4 mRNA negative expression[(2.49±0.83)ng/ml vs. (0.94±0.13)ng/ml](P<0.01). Conclusion The decline of the level of plasma PF4 and local lesion of PTC may be one of the reasons which can cause or promote cervical lymph node metastasis of PTC.
  • Related Articles

    [1]SUN Wenjia, YUE Junqiu, WANG Manxiang. Clinicopathological Characteristics and Therapeutic Effect of Patients with Non-small Cell Lung Cancer and Uncommon EGFR Mutations[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1221-1226. DOI: 10.3971/j.issn.1000-8578.2023.23.0431
    [2]XU Wenwen, ZHU Yuxi. Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1129-1134. DOI: 10.3971/j.issn.1000-8578.2021.21.0761
    [3]WU Bili, JIN Yu, ZHOU Xiao, YUAN Xianglin, LI Qianxia. Association Between Single Nucleotide Polymorphisms in ESR Pathway and Risk of Brain Metastasis in NSCLC with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2020, 47(10): 746-751. DOI: 10.3971/j.issn.1000-8578.2020.20.0837
    [4]HOU Ran, HU Po, SHI Jian. Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 471-476. DOI: 10.3971/j.issn.1000-8578.2020.19.0302
    [5]SU Yudong, CHEN Peng. Research Progress on Brain Metastases to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR-mutated Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 698-700. DOI: 10.3971/j.issn.1000-8578.2017.17.0240
    [6]LU Chang, SHEN Shujing, MAO Yuhuan, JI Yingying, LI Peipei, CAO Hui, WANG Ye, LI Xingya. Correlation of Tumor Markers with Clinical Efficacy of Advanced Lung Adenocarcinoma Patients with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 485-488. DOI: 10.3971/j.issn.1000-8578.2017.16.1530
    [7]XU Xiaoyan, XU Xianwei, WANG Hui, YANG Jinhua. Expression of PTEN and EMMPRIN in Lung Adenocarcinoma Tissues and Their Correlation with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 324-328. DOI: 10.3971/j.issn.1000-8578.2017.05.003
    [8]YANG Zhenhua, YE Liang, FANG Surong, GU Wei. Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 272-276. DOI: 10.3971/j.issn.1000-8578.2016.04.007
    [9]LIU Yongmei, ZHAO Qian, TANG Yuan, ZHANG Yan, LI Yanying, WANG Yongsheng, LU You. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Advanced Squamous Cell Lung Carcinoma Patients with Sensitive EGFR Mutations[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 911-914. DOI: 10.3971/j.issn.1000-8578.2015.09.011
    [10]GUO Tianxing, PAN Xiaojie, OU Debin, YE Mingfan. Relationship of Clinical Characteristics and EGFR, K-RAS Mutation in Lung Adenocarcinoma Patients with Predominant Ground-glass Opacity[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1313-1317. DOI: 10.3971/j.issn.1000-8578.2014.12.013

Catalog

    Article views (2600) PDF downloads (517) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return